Tango Therapeutics, Inc.
General ticker "TNGX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $491.8M (TTM average)
Tango Therapeutics, Inc. follows the US Stock Market performance with the rate: 42.4%.
Estimated limits based on current volatility of 4.4%: low 24.06$, high 26.28$
Factors to consider:
- Total employees count: 155 (+10.7%) as of 2024
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Supply chain disruptions, Regulatory and compliance, Limited operating history, Product development risks, Market competition
- Current price 114.4% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.78$, 12.42$]
- 2026-12-31 to 2027-12-31 estimated range: [3.68$, 9.91$]
Financial Metrics affecting the TNGX estimates:
- Positive: with PPE of -9.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -13.82 <= 0.07
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: Investing cash flow per share per price, % of -4.07 <= -0.65
- Negative: Industry earnings per price (median), % of -14.62 <= 0
- Negative: Inventory ratio change, % of 29.52 > 0.80
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term TNGX quotes
Long-term TNGX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $36.53MM | $42.07MM | $62.38MM |
| Operating Expenses | $150.70MM | $187.66MM | $173.67MM |
| Operating Income | $-114.17MM | $-145.59MM | $-111.29MM |
| Non-Operating Income | $12.56MM | $15.50MM | $9.70MM |
| R&D Expense | $115.20MM | $143.92MM | $132.16MM |
| Income(Loss) | $-101.61MM | $-130.09MM | $-101.59MM |
| Taxes | $0.13MM | $0.21MM | $0.00MM |
| Profit(Loss)* | $-101.74MM | $-130.30MM | $-101.59MM |
| Stockholders Equity | $253.11MM | $199.52MM | $346.18MM |
| Assets | $402.57MM | $316.49MM | $398.69MM |
| Operating Cash Flow | $-117.98MM | $-131.50MM | $-138.89MM |
| Capital expenditure | $1.53MM | $0.75MM | $1.05MM |
| Investing Cash Flow | $41.43MM | $86.13MM | $-40.87MM |
| Financing Cash Flow | $82.41MM | $47.66MM | $222.50MM |
| Earnings Per Share** | $-1.08 | $-1.19 | $-0.87 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.